Oxford-Emergent Tuberculosis Consortium signs commercial license agreement with Probiogen to explore production of MVA85A TB vaccine candidate using AGE1.CR.pIX® cell line
The Oxford-Emergent Tuberculosis Consortium Ltd., a joint venture between the University of Oxford and Emergent BioSolut…